Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins in children. Why and when.

E A Stein1

  • 1Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA. esteinmrl@aol.com

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cingulate circuits are associated with escalation of heroin use and naloxone-induced increases in heroin self-administration.

Addiction neuroscience·2023
Same author

Nicotine addiction: Translational insights from circuit neuroscience.

Pharmacology, biochemistry, and behavior·2021
Same author

Nicotine dependence (trait) and acute nicotinic stimulation (state) modulate attention but not inhibitory control: converging fMRI evidence from Go-Nogo and Flanker tasks.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2020
Same author

Delayed emergence of methamphetamine's enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence.

Drug and alcohol dependence·2016
Same author

Biomarkers for smoking cessation.

Clinical pharmacology and therapeutics·2013
Same author

A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback.

Genes, brain, and behavior·2013
Same journal

Impact of icosapent ethyl on serum lipoand glycoprotein profiles assessed by <sup>1</sup>H-NMR. A real-world observational study (IPE-NMR).

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same journal

Dysregulated growth hormone-insulin-like growth factor-1 axis in adults with metabolic dysfunction-associated steatotic liver disease: a meta-analysis.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same journal

Inclisiran-will it fulfill its promise?

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same journal

Incretin-based therapies and craving: a clinical signal pointing to reward reprogramming.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same journal

Joint associations of accelerometer-measured sleep duration and physical activity with cardiovascular disease and all-cause mortality: a longitudinal cohort study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same journal

Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
See all related articles

Familial hypercholesterolemia (FH) accelerates childhood atherosclerosis, posing significant risks. Statins show promise for treating pediatric FH, warranting guideline re-evaluation for earlier intervention in at-risk males.

Area of Science:

  • Cardiovascular Medicine
  • Pediatric Endocrinology
  • Genetics

Background:

  • Atherosclerosis originates in childhood, with familial hypercholesterolemia (FH) significantly accelerating its progression.
  • Untreated FH (homozygous and heterozygous) leads to substantial morbidity and mortality, with males experiencing earlier and greater risk.
  • Current pediatric treatment options like bile acid sequestrants have limitations in efficacy, tolerability, and FDA approval for pediatric use.

Purpose of the Study:

  • To review the evidence for atherosclerosis development in childhood, particularly in familial hypercholesterolemia (FH).
  • To evaluate the safety and efficacy of lipid-lowering therapies, specifically statins, in pediatric populations with FH.
  • To assess the need for re-evaluating current treatment guidelines for pediatric FH.

Related Experiment Videos

Main Methods:

  • Review of existing literature on childhood atherosclerosis and familial hypercholesterolemia.
  • Analysis of studies evaluating lipid-lowering agents, including bile acid sequestrants and statins, in children and adolescents.
  • Examination of a large, randomized, placebo-controlled study of lovastatin in adolescent males.

Main Results:

  • Familial hypercholesterolemia (FH) significantly accelerates atherosclerosis in children.
  • Statins have demonstrated efficacy and acceptable safety in pediatric studies, including a notable trial with lovastatin in adolescent males.
  • Existing treatments like bile acid sequestrants have limitations for pediatric use.

Conclusions:

  • Statins represent a viable therapeutic option for managing pediatric familial hypercholesterolemia (FH).
  • Earlier initiation of therapy, particularly in at-risk males around age 10, is recommended.
  • Further well-controlled studies are necessary to confirm clinical benefits and refine treatment guidelines for pediatric FH.